Topo Ⅱ在骨肉瘤中的表达及临床意义

The expression and clinical value of Topo Ⅱ in osteosarcoma

目的探讨Topo Ⅱ在骨肉瘤组织中的表达及其临床意义。方法应用免疫组化方法(S-P法)测定Topo Ⅱ在36例骨肉瘤和17例骨软骨瘤组织中的表达,并随访骨肉瘤患者生存时间。36例骨肉瘤中男19例,女17例,平均年龄19.9岁。Enneking分期Ⅱ_A 3例,Ⅱ_B 27例,Ⅲ_B 6例,并发病理性骨折7例。结果 36例骨肉瘤随访时间平均3年6个月,其中存活≥3年者13例,存活<3年者23例,死因均为骨肉瘤远处转移全身衰竭。36例骨肉瘤Topo Ⅱ阳性表达率为44.5%,明显高于骨软骨瘤组的11.8%(P<0.01)。Topo Ⅱ表达在不同Enneking外科分期组间无显著性差异(P>0.05),在生存时间3年以上组及3年以下组间有显著性差异(P<0.01)。结论 Topo Ⅱ表达可能与骨肉瘤细胞增殖活性有关,对骨肉瘤的化疗药物选择及预后评估具有一定价值。

Objective To investigate the expression and clinical value of Topo II in osteosarcoma. Methods Topo II was detected by using immunohistochemical method in 36 cases with osteosarcoma （19 males, and 17 females, mean age being 19.9 years） and 17 cases with osteochondroma. The cases with osteosarcoma were followed up. According to the Enneking staging, 3 cases were in stage IIA, 27 in stage IIB, and 6 in stage IIIB. Among them, 6 cases suffered from pathological fracture as complication, Results Of the 36 cases with osteosarcoma, the mean follow-up was 3 years and 6 months. 13 of the 36 patients survived for over 3 years, and 23 out of the 36 patients survived less than 3 years. They all died from whole-body failure caused by distant metastasis of osteosarcoma. 44.5% of the 36 cases with osteosarcoma reported positive in Topo 1I expression, which was significantly higher than 11.8% of the 17 cases with osteochondroma （P〈0.01）. There was no significant discrepancy in different Enneking staging groups /P〉0.05）, while there was significant difference in the two groups with different survival periods （P〈0.01）. Conclusions The expression of Topo II may be in collaboration with osteosarcoma cellular proliferation, and has clinical value for the option of chemotherapy medication and the assessment of the prognosis of osteosarcoma.